Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection
ID: NIH/NIAID 126Type: BOTH
Overview

Topic

Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451729

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) are seeking proposals for Small Business Innovation Research (SBIR) contract proposals. The specific topic of the solicitation is "Rapid Diagnostic Assays for Self-Monitoring of Acute or Rebound HIV-1 Infection".

The technology being solicited is focused on developing rapid diagnostic assays that can be used for self-monitoring of acute or rebound HIV-1 infection. The goal is to reduce the number of new HIV infections in the United States by 90 percent by 2030.

The typical applications of this technology would be widespread HIV testing to reduce undiagnosed HIV infection and connect people to HIV medical care as soon as possible. This will improve the health of people living with HIV and prevent transmission.

The solicitation is open for Phase I and Fast Track proposals, and direct-to-Phase II proposals will not be accepted. The anticipated number of awards is 4-5.

The budget for Phase I is $300,000 for up to 2 years, and for Phase II, it is $1 million for up to 3 years.

The deadline for proposal submission is November 14, 2023.

For more information and to access the solicitation, visit the following links:

  • SBIR Topic Link: Link
  • Solicitation Agency URL: Link
Files
No associated files provided.
Similar Opportunities
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, safety monitoring, and regulatory activities. The project duration is not specified, but the application due dates are provided. More information can be found on the grants.gov website.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus are pharmacotherapeutics (small molecules, biologics, natural products, etc.) and medical therapeutic and diagnostic devices (imaging technologies, therapeutic devices, diagnostic assays, etc.). The projects proposed should aim to establish technical feasibility, commercial potential, and the quality of performance of the small business awardee organization. The funding opportunity includes Phase I, Phase II, Fast Track, and Direct to Phase II applications. The deadline for applications is February 15, 2025. For more information and to apply, visit the grants.gov website or the solicitation agency URL provided.
Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for addressing health inequities in clinical diagnostics. The purpose of this funding opportunity is to encourage small businesses to develop improved or alternative clinical diagnostics that incorporate diverse patient groups and eliminate health disparities. The research should focus on identifying and addressing issues within clinical diagnostics that perpetuate health inequity. The projects may involve existing clinical diagnostics or propose new ones. Applicants are encouraged to consider social determinants of health during the development process and include input from relevant populations that experience health disparities. The funding opportunity accepts different types of projects, including those that address pigment variation in imaging devices, utilize equitable parameters instead of non-biological parameters like race, improve analytics or bioinformatics, develop clinical decision support tools, validate new technology, or further develop existing technology. The funding is available through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding options. The open date for applications is March 5, 2024, and the close date is January 6, 2027. For more information, including specific research objectives and areas of interest, interested parties can visit the solicitation agency URL provided.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for SBIR Phase IIB Bridge Awards to accelerate the development of cancer-relevant technologies toward commercialization. This funding opportunity aims to support small business concerns (SBCs) that have previously received SBIR or STTR Phase II awards from any Federal agency. The goal is to assist applicants in pursuing the next milestone necessary to advance a promising product or service along a commercialization pathway. The focus is on cancer therapeutics, imaging technologies, diagnostics, prevention and control tools, and model systems for cancer research. The funding will prioritize projects that have secured substantial independent third-party investor funds and those that require approval from a Federal regulatory agency. The application due date is August 21, 2024, and more information can be found at the solicitation agency URL: [link](https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-022.html).
Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for addressing health inequities in clinical diagnostics. The purpose of this funding opportunity is to encourage small businesses to develop improved or alternative clinical diagnostics that incorporate diverse patient groups and address health disparities. The goal is to lay the groundwork for more equitable clinical diagnostics that lead to improved health, healthcare delivery, and the elimination of health disparities. The research objectives include developing clinical diagnostics that are accessible to populations that experience health disparities, considering social determinants of health during the development process, and including input from relevant populations. The funding opportunity accepts various types of projects, such as novel technologies, analytics or bioinformatics, clinical decision support tools, and pilot or small-scale projects. The funding is available through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding options. The open date for applications is March 5, 2024, and the close date is January 6, 2027. More information can be found on the grants.gov website.